• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Baxter International (BAX) Is Drawing Fresh Attention, What Are Investors Missing?

    Simply Wall St·10/26/2026 12:25:34
    Listen to the news

    Why the FDA warning letter matters for Baxter International

    The FDA’s warning letter to Baxter International (BAX) puts detailed manufacturing and contamination issues at the Round Lake facility in focus. It raises fresh questions for investors around compliance, patient safety, and potential operational disruption.

    Recent trading reflects that tension. Baxter International’s share price has climbed 29.74% year to date and logged an 8.26% 1‑month share price return, yet the 5‑year total shareholder return is down 65.04%. This signals that long term holders are still carrying significant unrealised losses even as shorter term momentum has begun to rebuild.

    Scan how regulators and product risk are being priced across the sector by checking our curated 30 resilient stocks with low risk scores, built around balance sheet strength and cleaner risk profiles than Baxter International currently faces.

    Baxter International has rebounded sharply, yet long-term holders are still deep in the red. Has the recent climb already captured the repair story, or does the current valuation still leave meaningful room for further rerating once the warning letter risk is absorbed?

    Most Popular Narrative: 9% Undervalued

    Baxter International last closed at $25.30, while the most followed narrative anchors fair value at about $27.92 using an 8.9% discount rate. That gap suggests investors are still pricing in execution and regulatory risks even after the recent rebound.

    The main factor that needs to go right is that Baxter International translates its decentralization, Baxter GPS program, and balance sheet deleveraging into sustained cash generation without a relapse in hospital consumables or infusion related headwinds.

    See why 19 investors see Baxter International as 9% undervalued.

    Result: Fair Value of $27.92 (UNDERVALUED)

    Still, the Baxter International story can be knocked off course if Novum IQ pump issues drag on or if contract manufacturing bottlenecks continue to constrain injectables.

    Find out about the key risks to this Baxter International narrative.

    Next Steps

    Mixed messages run through the Baxter International story, which is exactly why you should review the underlying data yourself and move quickly to frame your own stance using the 3 key rewards and 1 important warning sign.

    Looking for more Baxter International investment ideas?

    If Baxter International sits on your watchlist, round out your research by lining up alternatives that offer different return profiles, risk levels, and income potential.